Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.

Abstract

PURPOSE Gemcitabine is a nucleoside analogue with activity against solid tumors. Gemcitabine metabolic inactivation is catalyzed by cytidine deaminase (CDA) or, after phosphorylation, by deoxycytidylate deaminase (DCTD). We set out to study the pharmacogenomics of CDA and DCTD. EXPERIMENTAL DESIGN The genes encoding CDA and DCTD were resequenced using DNA… (More)

Topics

12 Figures and Tables

Cite this paper

@article{Gilbert2006GemcitabinePC, title={Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.}, author={Judith A. Gilbert and Oreste Ezequel Salavaggione and Yuan Ji and Linda L. Pelleymounter and Bruce W. Eckloff and Eric D. Wieben and Matthew M. Ames and Richard M. Weinshilboum}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2006}, volume={12 6}, pages={1794-803} }